Lodestone is developing the next generation of its magnetic spectrometer for immediate detection of treatment response in immunotherapy clinical trials. The open design of the clinical spectrometer will support in vivo measurements with biosensor probes at depths of up to 15 cm. We envision that IRIS biosensor probes will be placed in the tumor environment to monitor biomarkers of the immune system’s response to the treatments.
Leverage our development services for customized in vivo assays and accelerate your pre-clinical research.
Request a Free Consultation